Search

Displaying results 1151 - 1160 of 1786 in total
  1. Drug

    Gadoteridol

    go.drugbank.com/drugs/DB00597
    ApprovedInvestigational

    [A263076] Initially approved by the FDA in 1992, gadoteridol received additional approval in 2020 for use in pediatric patients less than 2 years old.[L49876]

  2. Drug

    Mechlorethamine

    go.drugbank.com/drugs/DB00888
    ApprovedInvestigational

    The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL

    Categories: Chemical Warfare Agents
  3. Drug

    Atazanavir

    go.drugbank.com/drugs/DB01072
    ApprovedInvestigational

    Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.

  4. Drug

    Sugammadex

    go.drugbank.com/drugs/DB06206
    ApprovedInvestigational

    Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.

  5. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy.

    Products: Nra-betahistine
  6. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]

  7. Drug

    Glucosamine

    go.drugbank.com/drugs/DB01296
    Approved

    [A231894,A232289] It is currently not approved as a prescription product by the FDA, but is widely available over the counter.

  8. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    [A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products.

  9. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    [A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444]

  10. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    [A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551]